ENTA Enanta Pharmaceuticals, Inc.
$12.96▲ +2.05%
Healthcare
Other
After hours
$12.96▲ +0.00%
Sep 11, 7:30 PM ET
Volume 289.1K
Avg Volume (10D) 233.7K
Key Metrics & Fundamentals
Market Cap
$377.47M
P/E Ratio
–
Div Yield
–%
52W Range
7.05 - 17.15
% vs 50 MA
-3.77%
% vs 200 MA
-4.88%
RSI-14
43.4
MACD Histogram
-0.1100
Beta (1Y vs SPY)
1.04
Free Cash Flow
-$9.98M
Gross Rev
$14.36M
Gross Profit
$14.36M
EBITDA
-$14.15M
COGS
–
Operating Exp
$31.60M
Operating Income
-$17.24M
EBIT
-$17.24M
Pretax Income
-$19.47M
Net Income
-$19.50M
EPS (Diluted)
-0.67
Price & Volume History
Loading chart…
Recent News
Enanta Pharmaceuticals to Participate in September Investor Conferences
Business Wire · Sep 1, 2026 11:00 AM
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Zacks · Aug 10, 2026 9:10 PM
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Associated Press · Aug 10, 2026 8:06 PM
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Business Wire · Aug 10, 2026 8:01 PM
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 5, 2026 10:10 PM
Enanta Enters $75 Million At-the-Market Stock Offering Agreement
MT Newswires · Jul 2, 2026 9:26 PM
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Zacks · Jun 24, 2026 1:13 PM
Enanta Files Appeal in Ongoing Patent Dispute With Pfizer Over Paxlovid
MT Newswires · Jun 24, 2026 10:20 AM
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Business Wire · Jun 23, 2026 9:10 AM
Enanta Pharmaceuticals Advances RSV Drug to Phase 2/3 Trial After US FDA Meeting
MT Newswires · Jun 18, 2026 11:41 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See ENTA's money flow as a full page
Social Sentiment
No Reddit posts found for ENTA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.